Dare Bioscience
DARE
30 hedge funds and large institutions have $5.97M invested in Dare Bioscience in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.
2,290% more capital inflows, than outflows
Capital inflows: $4.56M | Capital outflows: $191K
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
7% more funds holding
Funds holding: 28 → 30 (+2)
7.1% more ownership
Funds ownership: 7.54% → 14.64% (+7.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$4.44M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$56.6K |
| 3 |
Jane Street
New York
|
+$17.1K |
| 4 |
Two Sigma Securities
New York
|
+$16.1K |
| 5 |
Zuckerman Investment Group
Chicago,
Illinois
|
+$15.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$149K |
| 2 |
Renaissance Technologies
New York
|
-$32.9K |
| 3 |
BlackRock
New York
|
-$7.59K |
| 4 |
Riggs Asset Management
Dallas,
Pennsylvania
|
-$456 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$228 |
DARE Hedge Fund Activity: Q3 2023 in Review
30 of the 6,317 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q3 2023, worth a combined $5.97M — up 0.83% from $5.92M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new DARE positions and 4 closed out — a net gain of 2 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $4.44M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $149K sold.
- 30 institutional investors held Dare Bioscience (DARE) as of Q3 2023, up from 28 in Q2 2023.
- Funds reported $5.97M of Dare Bioscience stock for Q3 2023, up 0.83% quarter-over-quarter.
- 6 funds opened new Dare Bioscience positions in Q3 2023 and 4 closed out, a net change of +2 holders.
- The largest Dare Bioscience buyer in Q3 2023 was Armistice Capital, an estimated $4.44M added.
- The largest Dare Bioscience seller in Q3 2023 was Susquehanna International Group, an estimated $149K sold.
Based on aggregated 13F filings for Q3 2023.